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ABSTRACT
While the functional disconnectivity hypothesis of schizophrenia has been the
subject of much study, very little is known about the contribution of individual genotypes
to connectivity between brain regions in either schizophrenia patients or in healthy
controls.
In this study, we obtained diffusion tensor imaging (DTI) maps and genome-wide
SNP data from 74 cases and 87 age- and gender-matched controls. Correlations were
performed between loading coefficients obtained from fractional anisotropy (FA) values
in networks of regions representing 6 maximally independent components and 134 SNPs
in genes that have been found to be important in myelination and/or schizophrenia. By
using independent component analysis (ICA) to analyze the FA data we move beyond
single voxels (voxel based morphometry) to a source based morphometry. In doing so,
we can obtain networks of FA values that covary in a similar way among subjects, and
we can study the relationship between these networks and genotype. We report one SNP
located in the intronic region of the metabotropic glutamate receptor 3 gene GRM3 that
showed a significant correlation with connectivity in patients but not in controls
(p<1.0x10-4). This SNP, rs7808623, has not been previously shown to be associated with
schizophrenia, although association has been shown with several SNPs in GRM3.
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CHAPTER 1: INTRODUCTION
Schizophrenia is a debilitating psychiatric disease that affects approximately 1%
of the population across the world. Psychiatrists characterize schizophrenia by the
presence of both positive and negative symptoms. Positive symptoms include
hallucinations and delusions, whereas negative symptoms include flat affect and
asociality. Schizophrenia heritability is thought to be approximately 50% based on twin
studies, with an apparently complex interplay occurring between genes and environment
(Brown, 2011; O’Connell et al., 2011). Because many of the risk factors for
schizophrenia occur during prenatal life, schizophrenia is widely thought to be a
developmental disorder. Adding strength to this hypothesis is the fact that the age of
onset for schizophrenia is usually in late adolescence.
The functional disconnectivity hypothesis of schizophrenia states that symptoms
of schizophrenia can at least in part be explained by a loss of connectivity between
dispersed brain regions. Studies investigating this hypothesis usually focus on myelin
integrity and oligodendrocyte development which are necessary for proper signaling of
the many myelinated tracts in the central nervous system. This hypothesis is attractive
because myelination of some tracts in the limbic system occurs in late adolescence, which
is the same time as the usual age of onset for schizophrenia (Benes, 1989). In addition,
both schizophrenia and myelination have been found to be affected by an interplay
between genes and the environment, with adverse environmental conditions decreasing
myelination and increasing risk for developing schizophrenia (Brouwer et al., 2010). The
functional disconnectivity hypothesis has been experimentally supported by several postmortem microarray analyses that have identified several genes in myelin and
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oligodendrocyte related pathways that are differentially expressed in the brains of
schizophrenia patients (e.g. Aston et al., 2004; Barley et al., 2009; Hakak et al., 2001;
Haroutunian et al., 2007). In most instances, myelin and oligodendrocyte genes have been
found to be expressed at a lower level in schizophrenia patients compared to controls. In
addition, pure demyelinating disorders, such as metachromatic leukodystrophy, can result
in psychosis when the age of onset occurs in late adolescence (Walterfang et al., 2005).
While most support for the functional disconnectivity hypothesis has come from
post-mortem studies, there have been several studies showing specific SNPs in myelin
related genes that are over-represented in people with schizophrenia compared to controls
(e.g. Buxbaum et al., 2008; Qu et al, 2008). For this study, we investigated the presence
of 134 SNPs from genes that have been previously shown to be involved in myelin and
oligodendrocyte function (Jungerius et al., 2008), as well as from genes that have been
shown to be associated with schizophrenia in general (http://www.szgene.org, see
Appendix A for a list of all SNPs).
Diffusion tensor imaging (DTI) is an application of magnetic resonance imaging
that uses magnetic gradients to infer information about water diffusion in living tissue
(Basser et al., 1994). In most tissues, including grey matter and ventricles in the brain,
water shows random, isotropic diffusion. However, fibrous tissues like myelinated axonal
tracts in the brain only allow water to diffuse along the axon of the fiber in an anisotropic
fashion. A measure of anisotropy of diffusion, called fractional anisotropy (FA), can be
used as a measure of the functional connectivity in each voxel of the DTI image.
Functional connectivity and FA change depending on axon myelination, axon diameter,
axon density, and/or directional coherence of axons (Basser, 1995). Although more than
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one factor can affect FA, it has generally been used in the literature as a marker of white
matter integrity and myelination. In agreement with post-mortem gene expression studies,
most studies have reported that patients with schizophrenia have lower FA values in at
least one white matter tract. In particular, the interhemispheric fibers, anterior thalamic
radiation (ATR), inferior longitudinal fasciculi, inferior frontal occipital fasciculi,
cingulum and fornix have all been implicated in schizophrenia by a recent meta-analysis
(Bora et al., 2011).
Following image acquisition, we used independent component analysis (ICA) to
process DTI data into maximally independent components (Arfanakis, 2002). ICA is a
blind source separation technique that is widely used in fMRI studies. Although ICA has
not been widely used in DTI studies, it may offer several advantages over traditional tract
–based data analysis techniques (Li et al., 2011). Firstly, as a data-driven technique, ICA
does not automatically treat FA values across whole tracts as constant averages.
Secondly, ICA does not assume independence of individual whole-tracts, an assumption
that both Wahl et al. (2010) and Li et al. (2011) showed to be untrue. Thirdly, as a
hypothesis free technique, ICA reduces dimensionality in a logical way without
discarding information across the brain. Finally, it has been suggested that ICA may be
more appropriate to discover group differences between patient and control groups
because individual components are determined by the variation of white matter across
subjects (Li et al., 2011). However, while our ICA results yielded 6 anatomically and
functionally relevant components, interpretation of these components requires care as it is
not as straightforward as tract based techniques.
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After obtaining biologically relevant independent components, we performed
multiple correlations of component loading coefficients with the genotypes of patients
and controls at 134 different SNP loci to ascertain any relationship between genotype and
white matter integrity (Figure 1). Because myelin integrity has been shown to be
decreased in patients with schizophrenia, we hypothesized that the genotypes of
individual SNPs in genes associated with white matter integrity or schizophrenia would
correlate with FA more strongly in our patient sample. We report one SNP, rs7808623,
which correlates significantly (corrected p<0.05) with white matter integrity in our
patient sample only. This correlation occurred in a component that contains a large
portion of the cortico-cerebellar-thalamic-cortical circuit, a circuit which has been
proposed to account for many of the diverse symptoms in schizophrenia (Andreasen et
al., 1998). Rs7808623 is located in an intronic region of GRM3, the gene encoding
metabotropic glutamate receptor 3. While polymorphisms in GRM3 have been shown to
be associated with schizophrenia (Cherlyn et al., 2010), any relationship between GRM3
genotype and myelination has not yet been investigated. This study supports others that
have shown a relationship between the glutamatergic system and white matter
development and function (Matute 2011; Wake et al., 2011) and is the first to investigate
the relationship between schizophrenia, functional connectivity, and genotype in many of
the original 134 SNPs.

4

Figure 1: Experimental design
Diffusion tensor images were obtained for a sample of schizophrenia patients and controls from 4 different
sites. ICA was then performed to obtain 20 independent components, six of which were determined to be
biologically meaningful. The loading coefficients of these components for each subject were then analyzed
for case/control differences, medication effects, symptom severity effects, and associations with genotype
in 134 myelin and schizophrenia related SNPs.
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CHAPTER 2: METHODS
Sample
The subjects for this study were participants in the Mind Clinical Imaging
Consortium (MCIC), a multi-site study involving investigators from New Mexico
(UNM), Iowa (IA), Massachusetts General Hospital (MGH), and Minnesota (MINN)
(Abbott et al., 2011). The cross section of individuals from the MCIC study with both
genetic and DTI data consisted of 75 cases and 87 controls matched for age and sex.
Unfortunately, these groups were not matched for race, and white/non-white status was
included as a covariate for all linear regression analyses that compared cases and controls
with no change in results. One case subject had to be excluded because of poor DTI
image quality, leaving a final sample of 74 subjects and 87 controls (Table 1).

Age
Mean (SD)
Range
Sex (M/F)
Race/Ethnicity
White
Black
Asian
Native American
Unknown

Schizophrenia
(n=74)

Controls
(n=87)

P value (test)

34.8 (11.1)
18-60
53/21

32.7 (11.2)
18-57
52/35

0.41 (Two sample
Kolmogorov-Smirnov test)
0.16 (Χ2 test)

50
15
4
1
4

77
3
3
0
4

8.1x10-4
(Fisher’s exact test)

Table 1: Demographic information for subjects used in this study. All subjects were members of the Mind
Clinical Imaging Consortium (MCIC)

All participants provided written informed consent, and the institutional review
board at each of the four sites approved this project. Participants in the control group
were negative for any medical, neurological, or psychiatric illnesses. All participants in
the patient group had received a diagnosis of schizophrenia, schizoaffective disorder, or
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schizophreniform disorder. This diagnosis was confirmed upon their entry into the study
using the Structured Clinical Interview for DSM-IV-TR Disorders (First et. al., 1997) or
the Comprehensive Assessment of Symptoms and History (Andreasen et al, 1992).
Patients were excluded if they had ever been diagnosed with any other psychiatric disease
or with epilepsy, had a history of head injury, had a history of inhalant use, showed
substance abuse or dependence within the past month, or had an intelligence quotient
equal to or less than 70.

Diffusion tensor imaging data acquisition and processing
Diffusion tensor imaging data was acquired at each of four sites: UNM, IA, MGH
and MINN. All sites except UNM used a Siemens 3 Tesla Trio Scanner. UNM used a 1.5
Tesla Sonata. All sites used a field of view of 256mmx256mm. UNM and MINN used
12 gradient directions with b=1000 s/mm2, whereas IA used 6 gradient directions with
b=1000 s/mm2, and MGH used 60 gradient directions with b=700 s/mm2. All sites
imaged 64 slices, except MGH which imaged 60 slices. DTI experiments were repeated
twice to increase signal-to-noise ratio.
The dicom2nii program found at www.sph.sc.edu/comd/rorden/dicom.html was
used to convert dicom files to nifti format. Dicom2nii also outputs gradient direction
tables after image slice orientation correction and a b-value table. Both DTI experiments
were combined into one 4D nifti file with a concatenated table of corresponding b-value
and gradient direction tables. Correction for Eddy currents was performed by registering
all the images to a b=0 s/mm2 diffusion image using FLIRT (FSL,
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www.fmrib.ox.ac.uk/fsl) with a mutual-information cost function. This algorithm
registers images of both the DTI measurements to a common image.
The diffusion tensor, scalar diffusion parameters (including FA) were calculated
using DTIFIT (FSL). The data was not averaged for this calculation. FNIRT (FSL), a
non-linear registration algorithm, was used to normalize the FA image of each subject to
a 1x1x1mm3 FA template (FMRIB58_FA_1mm) in the Montreal Neurological Institute
(MNI) space. This normalized data was then down-sampled to a 2mmx2mmx2mm
resolution and smoothed with a Gaussian kernel of 88 mm full width half maximum prior
to independent component analysis performance.

Independent component analysis
ICA analysis is a blind source separation technique that is widely used in imaging
studies, especially in fMRI. Briefly, ICA attempts to break data into maximally
independent components in order to ascertain sources within very large data sets. ICA
was performed in Matlab using Group ICA fMRI Toolbox (GIFT) software
(http://icatb.sourceforge.net) to extract 20 independent components from a subject-byvoxel FA matrix (Calhoun et al., 2001; Erhardt, et al., 2010; Li, et al. 2007; Xu, et al.
2009). We chose to set the number of components at 20 based on previous observations
by our lab group that this number works well with imaging data and returns biologically
meaningful components. Components were visualized using MRIcron, a visualization
tool freely available online at http://www.cabiatl.com/mricro/mricron/index.html.
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White matter characterization of biologically relevant independent components
The white matter tracts in each component were determined in three different
ways. Quantitatively, SPM8 was used to map each component to the John Hopkins DTI
atlas (Mori, et al., 2005). This allowed us to view the percent of 20 different tracts in
each component, as well as the percent of each component which was composed of each
of the 20 different tracts (see Table 2 for white matter tracts). Qualitatively, we also used
Mori et al.’s 2005 MRI Atlas of Human White Matter and http://www.dtiatlas.org (based
on Wakana et al., 2004) to map the regions in component B’s threshold map (Figures 2
and 9) to previously defined white matter tracts. This map represents the voxels that
contribute the most to the make-up of component B. The threshold was determined by
viewing which score was able to best eliminate artifacts while maintaining information
about white matter tracts across all slices of all six biologically relevant maps. The
qualitative analysis has the advantage of allowing us to visualize more than just the 20
white matter tracts from the SPM analysis, as well as to see the extent of connectivity
between these tracts.
Determination of symptom severity and white matter association in patient sample
The severity of positive and negative symptoms for the patient group was
assessed using the Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen,
1984) and the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen,
1983). Linear regressions were performed in R by modeling subjects’ ICA loading
coefficients as a function of positive, negative, or disorganized symptom scores, with site
set up as a series of indicator variables.
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Name of tract
Anterior thalamic radiation left
Anterior thalamic radiation right
Corticospinal tract left
Corticospinal tract right
Cingulum (cingulate gyrus) left
Cingulum (cingulate gyrus) right
Cingulum (hippocampus) left
Cingulum (hippocampus) right
Forceps major
Forceps minor
Inferior fronto-occipital fasciculus left
Inferior fronto-occipital fasciculus right
Inferior longitudinal fasciculus left
Inferior longitudinal fasciculus right
Superior longitudinal fasciculus left
Superior longitudinal fasciculus right
Uncinate fasciculus left
Uncinate fasciculus right
Superior longitudinal fasciculus (temporal part) left
Superior longitudinal fasciculus (temporal part) right

Abbreviation for tract
Left ATR
Right ATR
Left CST
Right CST
Left CGC
Right CGC
Left CGH
Right CGH
FMAJ
FMIN
Left IFO
Right IFO
Left ILF
Right ILF
Left SLF
Right SLF
Left UF
Right UF
Left SLFt
Right SLFt

Table 2: List of 20 tracts that were mapped to each of the biologically relevant components using SPM.
Atlas used for map was taken from John Hopkin’s DTI atlas (Mori et al., 2005)

Calculation of CPZ dose-year equivalent values in patient sample and regression with
ICA loading coefficients
Medication information was also obtained for each patient and converted to
lifetime CPZ equivalence values based on the expert consensus guideline presented by
Kane et al., 2003. Dose year of antipsychotics were calculated using the formula
described by Abbott et al., 2011:

Dose year=[(dose(mg)*100CPZ)/drugequivalent]*[daysondose/365.25]*[1year/(100CPZ*1year)]
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Following calculation of dose year equivalents, linear regression was once again
performed in R modeling ICA loading coefficient as a function of CPZ dose-year
equivalents with site as a covariate.
Statistical analysis of components prior to integration of genotype data
After components were determined, any differences based on site were assessed
using a one way ANOVA. Differences in components between cases and controls were
assessed using the following linear regression model:
Y= α + β1X1 + β2X2 + β3X3+ β4X4+ β5X5
Where Y is the subjects’ ICA loading coefficient values for each component, α is the
intercept, X1 is disease state, and X2-X4 are a series of indicator variables representing the
four different sites, and X5 is white/non-white status for each patient. P-values were
adjusted using a Bonferroni correction for 6 independent tests.
Effects of medication analysis and symptom severity on ICA loading coefficient
values in the patient sample were assessed using the following linear regression analyses:
Y= α + β1X1 + β2X2 + β3X3+ β4X4
Where Y is the subjects’ ICA loading coefficient value for each component, α is the
intercept, X1 is either lifetime medication use or symptom severity, and X2-X4 are a series
of indicator variables representing the four different sites. P-values were adjusted using a
Bonferroni correction for 6 independent tests.

Genetic analysis
All subjects were genotyped using an Illumina’s HumanOmni Quad Duo Chip. A
list of 288 myelin and/or schizophrenia related SNPs for further analysis was compiled
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using http://www.szgene.org, Jungerius et al. (2008) and various other literature sources.
Out of these 288, 140 were available from the Illumina Chip, although one failed quality
control (genotyping rate<95%), and five others were excluded because they had a minor
allele frequency of less than 5% in our sample. This left a final list of 134 myelin and/or
schizophrenia-related SNPs (Appendix A). Allele frequency differences between cases
and controls was determined using a Χ2 analysis, and no genotype was present at
differing rates in either sample (uncorrected p>.001). Linkage disequilibrium units for
Table 3 were determined using the HapMap project’s data within Applied Biosystems
SNPbrowser software (http://marketing.appliedbiosystems.com/mk/get/snpb_landing).

Linear regression analyses of genotype
Genotypes were either represented as number of major alleles (i.e., 0, 1 or 2 for
each SNP in each subject), or they were coded by presence of a minor allele (i.e., either 1
or 2). Pearson correlation coefficients and significance were then determined for each
SNP-component combination using R. Because of the need to correct for site, linear
regression was also performed modeling ICA loading coefficient value as a function of
genotype and site by fitting the following model:
Y= α + β1X1 + β2X2 + β3X3+ β4X4
Where Y is the subjects’ ICA loading coefficient values for each component, α is the
intercept, X1 is the number of major alleles for each genotype, and X2-X4 are a series of
indicator variables representing the four different sites. This type of test assumes an
additive model for major allele presence, although similar results were obtained when a
one-way ANOVA was performed for each SNP/component combination (without
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correcting for site). P values for coefficients of interest were adjusted using a Bonferroni
correction for 804 independent tests (134 SNPs * 6 components).
Additionally, ICA loading coefficient values were also modeled as a function of
genotype, medication level and site, as well as a function of genotype, age, sex,
handedness, race and site.
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CHAPTER 3: RESULTS
Independent Component Analysis
Out of the 20 independent components obtained, six were qualitatively
determined to be biologically meaningful (Figure 2 A-F). These components will
hereafter be referred to as components A-F corresponding with the order of their
appearance in Figure 2. The remaining 14 were excluded from further analysis on the
basis of having large portions of brain regions which appeared to be artifacts of different
brain/ventricle size among participants (Figure 2G). Having such a large number of
excluded components helps to assure that most of the noise caused by variation in size
along the edge of the brain is excluded from our actual analysis. Additionally, the edge of
the brain does not contain any large myelinated white matter tracts, so we could exclude
these components without fear of losing meaningful data.
We used SPM8 to quantitatively map the biologically meaningful components to
20 tracts defined in Johns Hopkins’s DTI atlas (Table 2, Mori et al., 2005). This allowed
us to view both the percentage of each tract in each component (Figure 3) as well as the
percentage of each component occupied by each tract (Figure 4). Tracts which are
especially represented in the biologically relevant components include the anterior
thalamic radiation (ATR), the corticospinal tract (CST), the forceps major (FMAJ),
forceps minor (FMIN), and the superior longitudinal fasiculus (SLF). Also, as can be
seen in Figures 2-4, left-right symmetry was largely maintained in each component. This
symmetry would be expected given that the same tracts on opposite sides of the brain
should covary with each other.
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Figure 2: Threshold map for all biologically meaningful components that were observed as a result of ICA
on multi-site DTI data (A-F) as well as an example of a non-biologically meaningful component (G). Color
represents the extent that each voxel contributes to the map of each component. The higher contributing
voxels from each biologically relevant component tend to be distributed symmetrically and along regions
of white matter tracts. The voxels above threshold in the non-biologically relevant components tended to be
present along the edge of the brain and may represent variation in brain size or in grey matter structure.
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Figure 3: SPM was used to map each component to a DTI atlas containing 20 different tracts (table 2). For
components A-F the percentage of each tract that is present in each component is shown.
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Figure 4: SPM was used to map each component to a DTI atlas containing 20 different tracts (table 2). For
components A-F the percentage of each component that is covered by each tract is shown.
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Site differences
We assessed the differences in DTI data between sites using a one-way ANOVA
for both cases and controls in each component (Figure 5). We found that the means of
ICA loading coefficients for the controls differed significantly (p<0.05) in each site, and
that the means of the ICA loading coefficients in the schizophrenia patients differed
significantly for four out of the six sites (p>0.1 for components B and C). In addition,
using the non-parametric Fligner-Killeen test of homogeneity of variances, we found that
the variances at components A, B, D, and F differed significantly both in the patient and
the control group. Because of these differences, all tests subsequently performed included
a correction for site. Because our results did not appear to change whether site was
treated as a fixed or a random effect, we treated site as a fixed effect for ease of
interpretation of our regression coefficients of interest (Bates, 2006).
Using a Χ2 analysis we assessed for any differences in allele frequencies between
sites. Twelve SNPs were determined to differ significantly (unadjusted p>0.05) by site,
none of which played a role in our results. These SNPs are marked with an asterisk in
Appendix A.

18

Figure 5: Box and whisker plots of the ICA loading coefficients for controls and cases at each site. The
variances among control subjects and among patient subjects at site differed significantly from each other in
every component except components C and E. The means of the ICA loading coefficients for the control
samples at each site differed significantly from each other in each component, and the means for the patient
sample differed from each other in all components except components B and C.
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Differences in ICA loading coefficients in patients versus controls
ICA loading coefficients in both components C and E were determined to
significantly differ between the patient group and the control group following a
Bonferroni correction for 6 independent tests (Figure 6, p=5.16x10-5 for component C
and p=3.68x10-5 for component E). As shown in Figures 3 and 4, component C contains a
disproportionate portion of the ATR, while component E contains a wide variety of white
matter tracts, including the ATR, the CST, the CGC, the SLF, and the right IFO. Given
that component E contains a large number of tracts, the significant difference seen
between white matter integrity in this component between patients and controls may be
reflective of a difference in global white matter integrity.

Effects of medication on ICA loading coefficient value in patient sample
We were able to collect information on lifetime medication use in 72 out of our
74 patient subjects and convert that information into lifetime CPZ-equivalent use in dose
years (Kane et al., 2003; Abbott et al., 2011). Because one subject had a lifetime CPZequivalent dose-year value that was more than 6 standard deviations above the mean, we
excluded that subject from our analysis.
We found that lifetime medication use was significantly associated with ICA
loading coefficients following a Bonferroni correction for 6 multiple comparisons in
components A and E (Figure 7, corrected p=0.0131for component A and 0.00599 for
component E). Interestingly, component E had also been found to differ between patients
and controls, indicating that the white matter in this component may be a target of
medication. As shown in Figures 3 and 4, component E contains a wide variety of white
matter tracts, whereas the CST comprises a large portion of component A.
20

Figure 6: Mean ICA loading coefficients in both components C and F differed significantly between
patients and controls when controlling for site (corrected p=5.16x10-5 for component C; corrected
p=3.68x10-5 for component E).
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Because 200 mg-years represented a natural break in our data (i.e., only three
patients reported medication levels above 200 mg-years), we ran the same linear
regression model but excluded patients whose lifetime CPZ equivalency dose-years were
higher than 200 to observe whether these three subjects were driving our findings. We
found that in component E medication levels were still associated with ICA loading
coefficient values at a threshold-significance level (Figure 7D, uncorrected p =0.0156,
corrected p=0.0936). A significant association between medication level and ICA loading
coefficient was no longer seen in component A (Figure 7B, corrected p=0.451).

Effects of symptom severity scores on ICA loading coefficient values in patient sample
For our patient sample we had access to both the SAPS and SANS ratings of
positive, disorganized, and negative symptom severity (Andreasen, 1983; Andreasen,
1984). We performed three linear regression analyses to assess any association between
ICA loading coefficient values and symptom severity scores. These models were similar
to the ones used to ascertain case/control differences and medication effects, but with X1
representing positive, negative or disorganized symptom severity score. Surprisingly, we
did not find any association between ICA loading coefficient values or symptom severity
scores in any of the six biologically relevant components.
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Figure 7: ICA loading coefficients for patient subjects in components A (A, B) and E (C, D) plotted as a function
of lifetime CPZ dose-year equivalent use. These components showed a significant association with lifetime CPZ
use when including site as a covariate (A, component A corrected p=0.0131; C, component E corrected p
=0.00599) . This association was no longer significant in component A when only including patients with a
lifetime CPZ equivalent of less than 200 mg-year (B, corrected p with site as a covariate=0.451), but was still
significant at a threshold level for component E (D, corrected p=0.0936, uncorrected p=0.0156)
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Effect of genotype on white matter integrity
After characterizing the independent components and their association with
disease state, medication level, and symptom severity, we next sought to establish
whether any of the six components showed an association with the genotypes of 134
myelin and schizophrenia related SNPs (Appendix A) in either the patient group or the
control group.
While there were no significant effects of genotype on FA found in the control
group, we report one highly significant association in the patient sample. The relationship
between rs7808623, located in an intronic region of GRM3, and component B was found
to be significant even after the stringent Bonferroni correction for 804 independent tests
(corrected p=0.0252, uncorrected p=3.14x10-5). The minor allele of rs7808623 was
associated with higher white matter integrity in component B (Figure 8A), which
contains portions of the ATR as well as the corticospinal tract (Figure 3B and Figure 4B).
The allele frequency for rs7808623 did not differ by site (Χ2 test, p=0.211). By mapping
the top-contributing voxels in component B slice by slice (Figure 9) and comparing these
slices with two different white matter atlases, we could see that component B represents a
series of tracts connecting the frontal cortex to the cerebellum and that these tracts
correspond to the cortico-cerebellar-thalamic-cortical circuit that has been implicated in
schizophrenia pathology (Andreasen and Pierson, 2008).
Because there was only one patient with a homozygous minor genotype (Figure
8A), we also performed a regression analysis wherein we grouped the homozygous minor
case with the heterozygous cases (Figure 8B). This design no longer represents an
additive model, but looks at the difference in mean ICA loading coefficient between
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subjects with or without at least one minor allele. We found that with this model the
association between rs7808623 and component B was still quite significant (uncorrected
p=6.75x10-5), although it no longer passed a Bonferroni correction at the p<0.05 level
(corrected p=0.0542). This association also remained significant when medication levels
were used as an additional covariate (corrected p=0.0469). Finally, this association
remained significant when using the demographic factors age, sex, handedness, and race
(‘non-hispanic white/other’ due to sample size) as covariates (corrected p=0.0249).
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Figure 8: Component B ICA loading coefficients for each subject in the patient group plotted as a function
of rs7808623 genotype (A, corrected p with site as a covariate=0.0252) Because there was only one patient
subject with a homozygous genotype for the minor allele, that subject was grouped with the heterozygotes to
show that the relationship between loading coefficient and genotype still exists (B, corrected p with site as a
covariate=0.0542, uncorrected p with site as a covariate=6.75x10 -5).
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Figure 9: Coronal slices in fixed intervals showing threshold map of component B, starting anteriorly in the
top right (A). Sagittal section without threshold map overlay showing interior and posterior boundaries of
coronal sections (B)
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CHAPTER 4: DISCUSSION
In this study, we obtained both diffusion tensor images and genotypes of 134
myelin and schizophrenia related SNPs in a sample of 74 schizophrenia patients and 87
age- and gender-matched controls. We hypothesized that SNPs in myelin and
schizophrenia-related genes would correlate with FA values in biologically relevant
independent components obtained from ICA of our DTI data. To our knowledge, this is
the first study to use ICA of DTI data to investigate any effect of genotype on FA. We
report one SNP, rs7808623, to be significantly associated with white matter integrity in
an independent component that contains a large proportion of the cortico-cerebellarthalamic-cortical circuit (Figure 9) that has long been associated with higher cognitive
processes and schizophrenia symptomology (Andreasen et al., 1998).

GRM3
GRM3, also known as metabotropic glutamate receptor 3 (mGluR3), is one of
eight metabotropic glutamate receptors (GRM1-8), which are in turn subdivided into
three groups based on sequence homology and signaling properties (Nakanishi, 1992;
Niswender and Conn, 2010). The metabotropic glutamate receptors appear to be
responsible for fine-tuning the actions of ionotropic glutamate receptors (Conn and Pin,
1997; Niswender and Conn, 2010). GRM3, along with GRM2, is a type II metabotropic
glutamate receptor and is expressed on the extrasynaptic membranes of presynaptic
glutamatergic (Mateo and Porter, 2007) and GABAergic (Mitchell and Silver, 2000)
neurons. GRM3 modulates the effects of glutamate spillover by decreasing further
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glutamate or GABA release, thereby either decreasing or increasing glutamate-mediated
excitation. Binding of GRM3 by glutamate activates Gi/o receptors which act to inhibit
further neurotransmitter release both by inhibition of adenylyl cyclase and by uncoupling
with Gβγ subunits which then directly activate K+ channels and inhibit Ca2+ channels
(Niswender and Conn, 2010). Because of its role as an inhibitory receptor on
glutamatergic neurons, GRM3 modulates firing of many different kinds of neurons that
are innervated by glutamatergic synapses. This includes dopaminergic and serotonergic
neurons, both of which are targets of atypical antipsychotics.
Rs7808623 is located in an intronic region of GRM3 and has not previously been
investigated for any functional consequence or association with schizophrenia or white
matter. To our knowledge no other studies looking at GRM3 polymorphisms and
schizophrenia have investigated the rs7808623 genotype in particular. Our report that
rs7808623 is associated with FA in schizophrenia subjects could indicate that either this
SNP is in linkage disequilibrium with another GRM3 SNP such as rs1476455, which has
been shown to be associated with schizophrenia symptom severity (Bishop et al, 2011,
see Table 3), or that rs7808623 itself has functional consequences. Intronic SNPs are
likely important in GRM3 expression because GRM3 is subject to alternative splicing
(Sartorius et al., 2006). While our study did not find a difference in any allele frequencies
between schizophrenia and control subjects, a positive association between allele
frequency and schizophrenia has been shown with at least three other polymorphisms in
GRM3 (Chen et al., 2005; Egan et al., 2004; Fujii et al., 2003; Mössner et al., 2008;
Schwab et al., 2008), although other studies have found no association between GRM3
polymorphisms and schizophrenia (Albalushi et al., 2008; Bishop et al., 2007; Fallin et
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al., 2005; Jönsson et al., 2009; Martí et al., 2002; Tochigi et al., 2006). Also, to the best
of our knowledge no other study has investigated a relationship between GRM3
polymorphisms and DTI in either schizophrenia patients or in healthy controls, though
other studies have reported a connection between GRM3 polymorphisms and
schizophrenia symptom severity/presentation (Bishop et al., 2011; Egan et al., 2004;
Jablensky et al., 2011; Mössner et al., 2008), response to medication (Bishop et al., 2005;
Fijal et al., 2009), brain activation patterns (Egan et al., 2004), and brain structure
(Haukvik et al., 2010). Table 3 shows the linkage disequilibrium units (LDUs)
determined by SNPbrowser between rs7808623 and selected other GRM3 SNPs reported
in the literature as having an association with schizophrenia. LDUs have been proposed
to be superior when representing variation of linkage disequilibrium with physical
location (Zhang et al., 2002) and for detecting patterns on a small scale (Ke et al., 2004).
A linkage disequilibrium block is defined by SNPbrowser as having an LDU value of less
than 0.3 (De La Vega et al., 2006). According to this definition, rs1476455 is the only
SNP in linkage disequilibrium with rs7808623 in the Caucasian HapMap sample.
Linkage disequilibrium in European-Americans has also been reported to extend
approximately 60KB (Reich et al., 2001), and both rs2299225 and rs1468412 were
reported by SNPbrowser to be within this range (Table 3). Given that these SNPs have
been shown to be associated with schizophrenia (Bishop et al., 2011, Chen et al., 2005,
Fujii et al, 2003), future studies will need to evaluate of the significance our geneticneuroimaging findings in a larger cohort of patients and control cases.
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SNP
rs1476455
rs2299225
rs2237562
rs1468412
rs2228595

LDUs to
rs7808623
0.00
(Caucasian)
0.32
(Caucasian)
0.17 (Chinese)
0.47
(Caucasian)
0.47
(Caucasian)
1.08 (Japanese)
0.64
(Caucasian)

Distance to
rs7808623

Association with
schizophrenia

Reference

61.586 KB

Symptom severity

Bishop et al.,
2011

42.574 KB

Allele frequency

Chen et al.,
2005

67.922 KB

Allele frequency (trend
level)

Schwab et al.,
2008

56.703 KB

Allele frequency

Fujii et al.,
2003

74.167 KB

Splice variant

Sartorius et
al., 2008

rs6465084

0.64
(Caucasian)

86.679 KB

rs274622

1.23
(Caucasian)

217.214 KB

rs724226
rs2189814
rs13242038

1.14
(Caucasian)
1.14
(Caucasian)
1.14
(Caucasian)

Allele frequency, global
symptom severity,
activation patterns during
working memory task,
attention
Negative symptom
improvement with
olanzapine treatment

164.78 KB

PANSS change following
risperidone treatment

158.398 KB

Cognitive deficit

202.734 KB

Hippocampal volume (not
schizophrenia specific)

Egan et al.,
2004;
Mössner et
al., 2008
Bishop et al.,
2005
Fijal et al.,
2009
Jablensky et
al., 2011
Haukvik et al.,
2010

Table 3: Selected GRM3 polymorphisms’ associations with schizophrenia and distances to rs7808623
in LDUs and MB. Distance was determined using Applied Biosystems’ SNPbrowser software.
Chinese or Japanese population is also reported if appropriate based on reference’s sample
population.

GRM3 has been shown to be expressed both in the prefrontal cortex and at lower
levels in dopaminergic neurons in the midbrain, although it does not appear to be
differentially expressed between schizophrenia patients and controls either in grey matter
or in white matter in the PFC (Ghose et al., 2008). Interestingly, agonists of type II
metabotropic glutamate receptors have been shown to be effective antipsychotics. In a
stage II clinical trial, an agonist of GRM3/GRM2 was shown to be statistically as
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effective as olanzapine in reducing symptoms of schizophrenia without the weight gain
side effect seen with olanzapine use (Patil et al., 2007). These agonists inhibit the large
increase in prefrontal cortex glutamate following treatment of mice with phencyclidine
(Moghaddam and Adams, 1998), and they inhibit the large increase in dopamine
signaling seen following treatment of mice with ketamine (Fell et al., 2011). These
findings suggest that GRM3/GRM2 agonists correct the signaling aberrancies that are
responsible for the symptoms of schizophrenia. Adding strength to this hypothesis is the
finding that both GRM2 and GRM3 knockout mice express more high affinity D2
receptors and are hypersensitive to dopamine neurotransmission (Seeman et al., 2009).
Although these pharmacological treatments target both GRM2 and GRM3, it has been
suggested that GRM3 especially is responsible for the antipsychotic properties based on
the fact that GRM3 polymorphisms, but not GRM2 polymorphisms, have been found to
be associated with schizophrenia in several studies (Harrison et al., 2008).
Association of GRM3 and decreased FA can be explained by a number of reasons.
Most obviously, FA decreases with decreased myelination by oligodendrocytes. Cultured
rodent oligodendrocyte progenitor cells (OPCs), cultured rodent oligodendrocytes (Luyt
et al., 2003; Deng et al., 2004), and adult human OPCs (Luyt et al., 2004) all express
GRM3, although any functional role in oligodendrocytes development or myelination has
not been completely defined (Luyt et al., 2006). In culture, GRM3 does not appear to be
developmentally regulated (Luyt et al., 2006), and more research is needed to determine
its functional role on oligodendrocytes. The GRM3 association that we observed with FA
in our patient sample could also be caused by a decreased number of axons in patients
with the TT genotype of rs7808623. Unfortunately, the developmental profile of GRM3
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in the human brain has yet to be determined, though it has been shown that astrocytic
GRM3 expression is necessary to protect neurons from NMDA-induced neurotoxicity
(Corti et al., 2007). This implies that reduced functionality of GRM3, which itself could
cause hyper-glutamatergic signaling, could also lead to increased neuronal damage as a
result of the aberrant signaling seen in schizophrenia.

Component B/ Cortico-cerebellar-thalamic-cortical circuit
The genotype/FA association we observed occurred in an independent component
that was dominated by white matter tracts connecting the internal capsule and the
thalamus to the cerebellar peduncles (Figure 9). Although the threshold map of this
component does not extend into the prefrontal cortex, component B is still very
reminiscent of the cortical-subcortical-cerebellar circuit that was proposed by Andreasen
et al. (1998) to be responsible for “cognitive dysmetria” in schizophrenia patients. This
circuit is now more often referred to as the cortico-cerebellar-thalamic-cortical circuit.
Although the cerebellum has been traditionally viewed as performing mainly balance and
motor tasks, it has become increasingly clear that the cerebellum is also involved in tasks
related to emotion and cognition (Andreasen and Pierson, 2008). Indeed, the cerebellum
has been shown to be active independent of its normal motor function during many
activities that are impaired in schizophrenia, including facial recognition (Andreasen et
al., 1996), cognitive problem solving and task improvement (Kim et al., 1994; Seidler et
al., 2002), emotion attribution (Schulte-Rüther et al., 2007), directed attention (Allen et
al., 1997), and working memory (Hayter et al., 2007). Additionally, cerebellar lesions
can lead to complex symptomology affecting higher cognitive functions (Schmahmann et
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al., 2007; Tavano et al., 2007). Therefore, an altered cortico-cerebellar-thalamic-cortical
circuit could be a potential source of many of the cognitive defects seen in schizophrenia.
Further evidence for a loss of connectivity between the cortex and the cerebellum
in schizophrenia comes from other diffusion tensor imaging studies that have reported
decreased FA in the white matter tracts within the cerebellum and of cortical-cerebellar
tracts (Kanaan et al., 2009; Liu et al., 2011; Magnotta, 2008; Solowij et al., 2011).
Additionally, several studies have reported reduced cerebellar volume in schizophrenia
(Greenstein et al., 2011; Keller et al., 2003; Nopoulos et al., 2009; Thomann et al., 2009),
and others have reported reduced blood flow during working memory tasks in regions
involved in cortical-subcortical-cerebellar connectivity (Bor et al., 2011; Kiehl et al.,
2005; Kim et al., 2009; White et al., 2011).
Although the prominence of the ATR in component B is not apparent from its
threshold map, it is worth noting that an analysis mapping each voxel in component B to
a DTI atlas mapped 48.4% of component B to either the left or right ATR, a tract that has
been reported to have reduced white matter integrity in other DTI and schizophrenia
studies (Figure 4, McIntosh et al., 2008; Bora et al., 2011). The ATR is located in the
medial portion of the anterior limb of the internal capsule, a tract that is also a part of the
cortico-cerebellar-thalamic-cortical circuit . The ATR relays information between the
mediodorsal nucleus of the thalamus and the prefrontal cortex (Mori et al., 2005), and
loss of integrity of the ATR in particular has been suggested as a partial explanation for
some symptoms of schizophrenia (Mamah et al., 2010). In addition to DTI studies in
schizophrenia patients, loss of anisotropy in the anterior limb of internal capsule has been
reported in temporal lobe epilepsy patients who suffer from psychosis (Sundram et al.,
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2010). Interestingly, although we found no statistical difference in white matter integrity
between our patients and controls in the independent component that strongly correlated
with rs7808623 in our patient sample, we did report a strong difference in anisotropy in
another component which contained a large proportion of the ATR (component C,
Figures 2C, 3C, 4C, and 6).

Negative results
Our study investigated several SNPs that have previously been shown to be risk
factors for schizophrenia (Appendix A), but we failed to show any differences in allele
frequencies between our case sample and our control sample. Also, polymorphisms in
both NRG1 (McIntosh et al., 2008A; Winterer et al., 2008) and its receptor ERBB4
(Konrad et al., 2008; Zuliani et al., 2011) have been shown to be associated with white
matter integrity, and we found no such association in our sample. Finally, while many
studies have reported an association between white matter integrity and symptom severity
(de Weijer et al., 2011; Miyata et al., 2011; Shin et al., 2006; Skelly et al., 2008), we
found no such association.

Study limitations
Multi-site studies allow for larger sample sizes, but may cause the risk of intersite variability. We found that both the variances and the means among the four sites
varied significantly, and so we included a site correction for all our analyses. However,
we lacked the sample size at any individual site to attempt to reproduce our findings in
any one site by itself. Also, our methods required us to correct for 804 independent tests
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in the genotype-DTI association study, increasing the possibility of a type II error.
Finally, although ICA has several advantages over traditional DTI analysis techniques, a
traditional region of interest study would be necessary to confirm a relationship between
GRM3 and the cortico-cerebellar-thalamic-cortical circuit.
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APPENDIX A: LIST OF SNPs INVESTIGATED
134 SNPs and their corresponding genes that were investigated for relationship with FA
in biologically relevent independent components.

SNP
rs1801133

GeneSymbol
MTHFR

rs6691840
rs364482

GRIK3
EIF2B3

rs2661319
rs6660593
rs4951161
rs1800896
rs841865
rs752016
rs7520974
rs2919129
rs6715980
rs7601625
rs10496037
*rs2920898
rs2421954
rs2278718
rs7560571
rs16944
rs1344706
rs6435659

RGS4
CNTN2
CNTN2
IL10
PLXNA2
PLXNA2
CHRM3
RTN4
RTN4
RTN4
RTN4
RTN4
C2ORF86
MDH1
MAL
IL1B
ZNF804A
ERBB4

rs7588431

ERBB4

rs7598440

ERBB4

rs839523

ERBB4

rs707284

ERBB4

rs6436310
rs2305234
rs7372209

PAX3
ARPP21
CTDSPL

Gene name
5,10-methylenetetrahydrofolate reductase
(NADPH)
glutamate receptor, ionotropic, kainate 3
eukaryotic translation initiation factor 2B,
subunit 3 gamma, 58kDa
regulator of G-protein signaling 4
contactin 2 (axonal)
contactin 2 (axonal)
interleukin 10
plexin A2
plexin A2
cholinergic receptor, muscarinic 3
reticulon 4
reticulon 4
reticulon 4
reticulon 4
reticulon 4
chromosome 2 open reading frame 86
malate dehydrogenase 1, NAD (soluble)
mal, T-cell differentiation protein
interleukin 1, beta
zinc finger protein 804A
v-erb-a erythroblastic leukemia viral oncogene
homolog 4
v-erb-a erythroblastic leukemia viral oncogene
homolog 5
v-erb-a erythroblastic leukemia viral oncogene
homolog 6
v-erb-a erythroblastic leukemia viral oncogene
homolog 7
v-erb-a erythroblastic leukemia viral oncogene
homolog 8
paired box 3
cyclic AMP-regulated phosphoprotein, 21 kD
CTD (carboxy-terminal domain, RNA
polymerase II, polypeptide A) small
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rs3772917
rs1370807
rs1700
rs8177191
rs1799852
*rs1358024
rs1115219
rs1477211
rs6794467
rs2070022
rs2070016
rs875462
rs6913660
rs6932590
rs29228
rs2252711
rs3130375
rs3131296
rs11759115

GAP43
GAP43
FSTL1
TF
TF
TF
TF
CLDN11
CLDN11
FGA
FGA
DTNBP1
MHC REGION
MHC REGION
MOG
MOG
MHC REGION/
TCF4
NOTCH4
MDGA1

rs2064430
rs1475069
rs2758331
rs9456869
rs6964705
rs6465084
rs7808623
rs1045642

AHI1
AHI1
SOD2
QKI
EGFR
GRM3
GRM3
ABCB1

rs1128503

ABCB1

rs7341475
*rs1196475

RELN
PTPRZ1

*rs11136442

ARHGEF10

rs4876268

ARHGEF10

rs2270641

SLC18A1

rs35753505

NRG1

phosphatase-like
growth associated protein 43
growth associated protein 43
follistatin-like 1
transferrin
transferrin
transferrin
transferrin
claudin 11
claudin 11
fibrinogen alpha chain
fibrinogen alpha chain
dystrobrevin binding protein 1
major histocombatibility complex region
major histocombatibility complex region
myelin oligodendrocyte glycoprotein
myelin oligodendrocyte glycoprotein
Major histocombatibility complex region/
transcription factor 4
notch homolog 4
MAM domain containing
glycosylphosphatidylinositol anchor 1
Abelson helper integration site 1
Abelson helper integration site 1
superoxide dismutase 2, mitochondrial
quaking homolog, KH domain RNA binding
epidermal growth factor receptor
glutamate receptor, metabotropic 3
glutamate receptor, metabotropic 3
ATP-binding cassette, sub-family B
(MDR/TAP), member 1
ATP-binding cassette, sub-family B
(MDR/TAP), member 1
reelin
protein tyrosine phosphatase, receptor-type, Z
polypeptide 1
Rho guanine nucleotide exchange factor (GEF)
10
Rho guanine nucleotide exchange factor (GEF)
10
solute carrier family 18 (vesicular monoamine),
member 1
neuregulin 1
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rs4452759
rs6994992
rs10503929
rs3925
rs6996321
rs2272648
rs1011784
rs913767
rs306761
rs306770
rs3793753

NRG1
NGR1
NRG1
FGFR1
FGFR1
NDRG1
HSA-MIR-23B
GSN
GSN
GSN
PIP5K2A

*rs885834
rs762571
rs2299939

CHAT
PSAP
PTEN

rs2797986
rs4917450
*rs521674
rs2429511
rs2912787
rs2981428
rs1800955
rs6578993
rs1800532
rs6265
rs1602565
rs6277
*rs6275
rs1076560
rs2071521
rs12807809
*rs3016384

PLCE1
PLCE1
ADRA2A
ADRA2A
FGFR2
FGFR2
DRD4
TH
TPH1
BDNF
INTERGENIC
DRD2
DRD2
DRD2
APOC3
NRGN
OPCML

rs705708

ERBB3

rs4623951
rs6311
rs1130233

DAO
HTR2A
AKT1

rs3803300

AKT1

neuregulin 1
neuregulin 1
neuregulin 1
fibroblast growth factor receptor 1
fibroblast growth factor receptor 1
N-myc downstream regulated 1
homo sapiens microRNA-23-B
gelsolin (amyloidosis, Finnish type)
gelsolin (amyloidosis, Finnish type)
gelsolin (amyloidosis, Finnish type)
phosphatidylinositol-4-phosphate 5-kinase type
II-alpha
choline acetyltransferase
prosaposin
phosphatase and tensin homolog; phosphatase
and tensin homolog pseudogene 1
phospholipase C, epsilon 1
phospholipase C, epsilon 1
adrenergic, alpha-2A-, receptor
adrenergic, alpha-2A-, receptor
fibroblast growth factor receptor 2
fibroblast growth factor receptor 2
dopamine receptor D4
tyrosine hydroxylase
tryptophan hydroxylase 1
brain-derived neurotrophic factor
N/A
dopamine receptor D2
dopamine receptor D2
dopamine receptor D2
apolipoprotein C-III
neurogranin (protein kinase C substrate, RC3)
opioid binding protein/cell adhesion moleculelike
v-erb-b2 erythroblastic leukemia viral oncogene
homolog 3 (avian)
D-amino-acid oxidase
5-hydroxytryptamine (serotonin) receptor 2A
v-akt murine thymoma viral oncogene homolog
1
v-akt murine thymoma viral oncogene homolog
1
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rs3087454
rs1355920
*rs2135551
rs4784642

CHRNA7
CHRNA7
ADAMTSL3
GNAO1

cholinergic receptor, nicotinic, alpha 7
cholinergic receptor, nicotinic, alpha 7
ADAMTS-like 3
guanine nucleotide binding protein (G protein),
alpha activating activity polypeptide O
rs1801200
ERBB2
v-erb-b2 erythroblastic leukemia viral oncogene
homolog
rs2070106
CNP
2',3'-cyclic nucleotide 3' phosphodiesterase
rs4796751
CNP
2',3'-cyclic nucleotide 3' phosphodiesterase
rs2258689
MAPT
microtubule-associated protein tau
rs734194
NGFR
nerve growth factor receptor (TNFR
superfamily, member 16)
rs1860985
PRKCA
protein kinase C, alpha
rs3813065
PIK3C3
phosphoinositide-3-kinase, class 3
rs470826
MBP
myelin basic protein
rs4890875
MBP
myelin basic protein
rs470131
MBP
myelin basic protein
rs509620
MBP
myelin basic protein
rs2282557
MBP
myelin basic protein
rs4890876
MBP
myelin basic protein
rs2301600
MAG
myelin associated glycoprotein
rs3746248
MAG
myelin associated glycoprotein
rs720308
MAG
myelin associated glycoprotein
rs405509
APOE
hypothetical LOC100129500; apolipoprotein E
rs7412
APOE
hypothetical LOC100129500; apolipoprotein E
rs6140671
PLCB1
phospholipase C, beta 1 (phosphoinositidespecific)
rs762178
OLIG2
oligodendrocyte lineage transcription factor 2
*rs1059004
OLIG2
oligodendrocyte lineage transcription factor 2
rs737865
TXNRD2
thioredoxin reductase 2
rs4680
COMT
catechol-O-methyltransferase
rs701427
RTN4R
reticulon 4 receptor
rs1567871
RTN4R
reticulon 4 receptor
rs165862
PIK4CA
phosphatidylinositol 4-kinase, catalytic, alpha
rs165793
PIK4CA
phosphatidylinositol 4-kinase, catalytic, alpha
rs139884
SOX10
SRY (sex determining region Y)-box 10
rs475827
PLP1
proteolipid protein 1
rs471416
PLP1
proteolipid protein 1
*rs6571291
ABCD1
ATP-binding cassette, sub-family D (ALD),
member 1
*rs4129148
CSF2RA
colony stimulating factor 2 receptor, alpha, lowaffinity (granulocyte-macrophage)
*Allele frequency for genotype at SNP differed significantly by site (p<0.05, Χ2 test)
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